Results of the AGAVE-201 trial demonstrate a high incidence of response to axatilimab among patients with chronic graft-versus-host disease.

The HYPOSIB trial supports moderately hypofractionated radiotherapy with simultaneous boost as a standard-of-care option that’s noninferior to sequential boost, said study discussant Kimberly Corbin, ...

In an adjusted analysis, omitting the 5-FU bolus decreased the risk of neutropenia and thrombocytopenia without impacting overall survival. Omitting the 5-fluorouracil (5-FU) bolus from 5-FU multidrug ...

Results of a secondary analysis of data from the ASPREE trial quantified the CVD burden for older adults after cancer and its treatment.

Researchers sought to determine whether high antimetabolite dose intensity is related to higher treatment-induced toxicity in pediatric patients with ALL.

The hormone sensitivity of breast tissue makes it even more susceptible to damage from ionizing radiation from imaging ...

Researchers conducted a cross-sectional study to assess the prevalence of gender-affirming surgeries among transgender and gender-diverse children in the US.

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes than patients who received VRd alone.

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

These dedicated nursing roles can enhance care management of hospitalized patients undergoing radiotherapy and improve ...

A meta-analysis of studies showed netupitant-palonosetron more effectively prevented CINV, particularly in the overall and delayed phases, compared with aprepitant.

Researchers aimed to identify a standardized practice for the early detection of cutaneous melanoma recurrence.